← Issue №14/ week of Oct 4, 2026/Hepatology

Distinct Plasma Proteomic Signatures Distinguish MASLD From Non-Steatotic Individuals but Not From MetALD.

From GI Signals issue №14: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology prospective cohort · n=952 · Oct 1, 2026 · Liver International · IF 6.7

Distinct Plasma Proteomic Signatures Distinguish MASLD From Non-Steatotic Individuals but Not From MetALD.

Basic sciencebiomarkerepidemiologybasic sciencetranslational
Clinical takeawayNo clinical action yet: a mechanistic finding identifying proteomic signatures in MASLD and MetALD. Further validation and larger studies are needed to assess clinical utility.
What it foundMASLD showed 17 upregulated and 3 downregulated proteins vs controls, including leptin (LEP), FABP1, ACY1, and IGFBP1, but no proteomic distinction from MetALD.
ContextChallenges the current clinical thresholds for distinguishing MASLD from MetALD, suggesting proteomic profiles may not support a molecular distinction under these definitions.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Jakhar N … Schneider CV · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗Permalink
← Read the whole of issue №14 Every paper GI Signals surfaces gets a page like this one. All issues